

ANTARES PHARMA, INC.
Form 8-K
August 11, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2016

ANTARES PHARMA, INC.

(Exact name of registrant specified in its charter)

| | | |
|------------------------------|--------------|---------------------|
| Delaware | 1-32302 | 41-1350192 |
| (State or other jurisdiction | (Commission | (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |

| | |
|--|------------|
| 100 Princeton South, Suite 300, Ewing, | |
| NJ | 08628 |
| (Address of principal executive offices) | (Zip Code) |

Registrant's telephone, including area code: (609) 359-3020

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: ANTARES PHARMA, INC. - Form 8-K

- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: ANTARES PHARMA, INC. - Form 8-K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 5, 2016, Antares Pharma, Inc. (the “Company”) received a written notice of resignation from James E. Fickenscher, the Company’s Senior Vice President and Chief Financial Officer. Mr. Fickenscher’s resignation will become effective September 4, 2016. Mr. Fickenscher is resigning from the Company to pursue other interests, and his resignation is not a result of any dispute or disagreement with the Company. The Company has initiated a search for a new Chief Financial Officer.

Upon Mr. Fickenscher’s departure, Keith Muckenhirn, age 53, the Company’s Vice President, Finance and Corporate Controller since 2011, will assume the roles of interim Chief Financial Officer, principal accounting officer and principal financial officer while the Company completes its search process for a permanent Chief Financial Officer. Mr. Muckenhirn joined the Company in 2001 as Controller and has more than 30 years of experience in accounting and financial reporting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTARES PHARMA, INC.

Date: August 11, 2016 By: /s/ Peter J. Graham

Name: Peter J. Graham

Title: Senior Vice President, General Counsel,

Chief Compliance Officer, Human Resources, and Secretary